Bioprinting Tissue Constructs with Hydrogel Bioinks: A Protocol

Thick tissues (1 cm like human heart) face oxygen diffusion limitations causing core cell death. The bottom-up approach solves this by creating thin vascularized layers separately: electrospun fibers with laser-patterned grooves for aligned cardiomyocytes, endothelial cell channels, and drug-releasing particle structures. These layers are cultured independently then assembled into thick vascularized tissues just before transplantation. This ensures proper oxygenation and vascularization throughout the engineered tissue.

Without vascularization, only the outer 500-800 microns of thick tissue survives. Printed vascular networks enable oxygen perfusion throughout dense cellular tissues. Cardiac organoids (80% cardiomyocytes, 20% stromal cells) beat asynchronously when isolated but synchronize when assembled and perfused. By writing coronary artery-like vessels into cardiac tissue and flushing sacrificial material, researchers create perfusable channels. After 16 days of perfusion, centimeter-tall cardiac tissue beats visibly. This demonstrates creating functional, perfused cardiac constructs capable of drug testing and eventual implantation.

Electrical impedance spectroscopy enables non-invasive, real-time monitoring of 3D cell cultures by measuring electrical impedance responses to applied currents, distinguishing between 2D and 3D cultures and detecting biomaterial presence. For vascularization modeling, two approaches exist: non-porous microwells enable faster vascularization through direct cell contact, while porous microwells provide controlled interaction where pore density determines vascularization extent. Both approaches show abundant vascularization with endothelial cells forming 3D sprout-like structures. This vascularization capability is essential for modeling highly vascularized tissues like bone, enabling simultaneous study of multiple biological processes in engineered tissue constructs.

Tissue engineering develops biological substitutes to restore, maintain, or improve function, requiring cells, scaffolds, and bioactive molecules. Oxygen diffusion limits thick tissue viability—cells die beyond 100 microns from capillaries. Two approaches address vascularization: bottom-up prevascularization using endothelial cells on alginate beads forming vessel networks requiring feeder cell stabilization, which successfully connects to host vasculature upon implantation; and top-down 3D bioprinting using photopolymerization or extrusion to create defined vascular architectures. Mechanical stimulation enhances tissue development—chondrocytes in dynamically stimulated alginate disks develop greater stiffness, and perfused bone constructs show increased mineralization. These technical foundations enable progressing from simple constructs toward complex functional tissues.

Vascularized tissue engineering combines fugitive ink technology with cell-laden bioinks and extracellular matrix materials. The process involves printing sacrificial channels that are later removed, leaving empty lumens lined with endothelial cells (human umbilical vein endothelial cells). Multiple cell types including fibroblasts can be co-printed and subsequently populated into separate vascular compartments. Initial experiments showed some cell degradation during printing, but optimized matrices now achieve 95% cell viability. The resulting constructs demonstrate confluent endothelial lining with tight junctions, proper barrier function preventing uncontrolled diffusion, and support for angiogenesis when growth factors are introduced. These advances enable creation of centimeter-thick tissues with pervasive vascular networks suitable for long-term perfusion studies.

Two approaches exist for FDA regulatory pathways for bioprinted therapies: (1) For standardized bone implants, the process occurs in GMP facilities with FDA approval for printing standardized versions; (2) For autologous therapies like diabetic foot ulcer skin regeneration, the in-hospital manufacturing process approval pathway is used, which involves minimal manipulation of patient-derived stem cells (not cultured but applied directly to wound beds to prime regeneration). This approach allows faster clinical application without lengthy biologics or cell therapy approval processes. Clinical studies are ongoing in India, Korea, California (USC), Turkey, and Egypt.

Bioprinted therapeutic tissues represent a novel regulatory category neither purely drug nor medical device, fitting within FDA's Office of Tissues and Advanced Therapies (OTAT) purview. The pathway involves filing an Investigational New Drug (IND) application, anticipated around calendar year 2020, followed by clinical trial initiation. Scaling strategies involve two approaches: multiple patches or single patient-specific patches. Modular design enables fabrication to size based on individual anatomy, particularly valuable for rare orphan diseases where patient-specific construction is anticipated.

Translating bio-printing technology to clinical practice faces multiple barriers: the need for multidisciplinary teams combining expertise in computer science, chemistry, cell biology, and mechanical engineering; the absence of clinically certified bio-printers for medical use; and complex regulatory frameworks that create high barriers to entry. The regulatory environment, designed for traditional medical products, creates challenges for bio-printed tissues that may not fit existing categories. Additionally, the technology requires significant investment (5-10 years) that both academic research and industry may be reluctant to provide. Emerging applications include beta-cell replacement for diabetes treatment, where researchers have created insulin-producing cells responsive to glucose concentration that can be transplanted under the kidney capsule. Hair follicle regeneration represents another promising application, with stem cells grown in specialized bioreactors and implanted using robotic systems.

Organovo's technology serves two primary application categories. In vitro applications focus on creating human tissue models for pharmaceutical research, including preclinical safety testing and disease modeling. The company operates a service model where pharmaceutical companies send drug candidates to be tested on bioprinted tissues, with results ranging from basic survival indicators to detailed histological pathology analysis. In vivo applications involve developing therapeutic tissues for transplantation, with the goal of creating tissue sections that could deliver 10-15% of organ function to delay or avoid transplantation needs. Potential applications include liver tissue, blood vessels, nerve grafts, and heart muscle patches. The company allocates approximately 10% of R&D to early preclinical animal research in this area.

Bioprinted tissue products follow distinct regulatory pathways based on intended use. Research-use products require end-user licenses, while clinical applications demand FDA approval and GMP manufacturing standards. Xeno-free bioinks present straightforward pathways toward human translation, with successful implantation already demonstrated in clinical settings. Future directions include expanding into skin grafts for burn patients and gut models for disease research. Strategic collaborations with established companies and access to appropriate manufacturing facilities are critical for advancing bioprinted tissues from research to clinical applications.

Multimaterial cryogenic bio printing enables simultaneous deposition of different materials within the same structure. Coaxial nozzles create vascular-muscle junction units with distinct cellular compartments. The cryogenic environment maintains structural integrity during multimaterial deposition. Vertical printing creates hierarchical structures with aligned microchannels guiding cell alignment. These approaches enable fabrication of complex tissue interfaces better mimicking native organization, addressing limitations of single-material approaches while maintaining the advantages of cryogenic preservation.

Advanced bioprinting technologies enable fabrication of increasingly complex tissue constructs. The BioX6 bioprinter introduces coaxial printing using dual-nozzle systems with outer and inner needles, enabling simultaneous deposition of multiple bioinks to create layered structures. Sacrificial ink approaches allow creation of hollow tube structures that can later be dissolved, while crosslinking solutions enable formation of perfusable channels. Multi-material bioprinting combines different printheads to construct heterogeneous tissues, exemplified by skin models with distinct regions printed from different bioinks. These capabilities expand the range of achievable tissue architectures, supporting development of more physiologically relevant organoid models for research and therapeutic applications.

Advanced bioprinting techniques include FRESH (printing in gelatin micro-particle suspensions then melting support material), coaxial nozzles for simultaneous multi-material extrusion, and handheld biopens for in situ printing during surgery. Multi-material printing enables computer-controlled delivery of different components through single nozzles. Two-photon polymerization achieves 1-micron resolution for intricate structures. These technologies enable creation of complex constructs including vascular channels, nephron-like structures, and multi-cellular tumor models with precise spatial organization of different cell types and materials.

Extrusion-based bioprinting deposits bioinks containing cells and biomaterials through a nozzle to create 3D structures automatically. Rapid multi-material bioprinting uses a single nozzle with multiple inlet channels to deliver different materials simultaneously, eliminating the need for time-consuming nozzle exchanges. This enables printing of complex constructs with multiple cell types and materials in a single process, achieving 70-80% cell viability after seven days of culture. Digital Light Processing (DLP) bioprinting uses photoactivatable bioinks where light exposure causes cross-linking layer-by-layer. Multi-material DLP bioprinting enables creation of complex vascularized tumor models with endothelial cells lining channels and cancer cells in surrounding regions. Sacrificial bioprinting creates hollow perfusable channels by first printing sacrificial fibers that template channels, then removing them to create pathways lined with endothelial cells forming tight junctions that regulate molecule diffusion.

Bioprinting enables the fabrication of complex, functional tissue constructs by combining multiple materials and cell types in precise spatial arrangements, addressing the fundamental challenge of scaling up tissue engineering constructs beyond 200-300 micron oxygen diffusion limits through multi-material printing approaches that integrate structural supports, vascular networks, and cellular components.